Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 12/20 | 0.43 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | IARS1 | P41252 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4284558 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL4284560 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL76740 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL5420866 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL1599029 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL233325 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| Hydrochloric Acid SCHEMBL31084736 | 1.00 | DPP4 (0.43) | DPP4DPP8DPP9IARS1CA1 | |
| SCHEMBL76741 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9IARS1CA1 | |
| SCHEMBL1770623 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9IARS1CA1 | |
| SCHEMBL1770627 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9IARS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899137-A | Method for preparing Fmoc-Ile-OH by chemical derivatization | 杭州湃肽生化科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119504883-A | Synthesis method of RNA monomer intermediate 2' -fluoro-nucleoside modifier | 安徽信佰生物医药科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119241617-A | 2 '-Deoxy-2' -fluoro-N4-substituted cytidine compound, preparation method and application thereof | 河南省科学院高新技术研究中心 | 2025-01-03 | — | — | CN | claimed |
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-102262124-A | Method for detecting content of L-isoleucine methyl ester hydrochloride | — | 2011-11-30 | — | — | CN | claimed |
| EP-0397652-B1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORP (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0397652-A4 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | — | 1991-04-03 | — | — | EP | claimed |
| EP-0397652-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID. | GENZYME CORP (US) | 1990-11-22 | — | — | EP | claimed |
| US-4937270-A | Water insoluble derivatives of hyaluronic acid | GENZYME CORPORATION (US) | 1990-06-26 | — | — | US | claimed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | claimed |
| CN-119409587-B | Amino acid derivative of 2,2 '-binaphthyl-6, 6' -dicarboxylic acid, and preparation method and application thereof | Renmin Hospital Of Wuhan University (hubei General Hospital) (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250367169-A1 | FORMULATIONS FOR PERSONALIZED METHODS OF TREATMENT | FAETH THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | CYTOKINETICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2025-09-25 | — | — | US | disclosed |
| WO-1989002445-A1 | WATER INSOLUBLE DERIVATIVES OF HYALURONIC ACID | GENZYME CORPORATION (US) | 1989-03-23 | — | — | WO | disclosed |
| US-4657893-A | ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4616002-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0147211-A2 | 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNI3, TNNC1 | DPP4 2115/4885CA2 1044/4885DPP8 2776/4885 |
| US-12441691-B2 | Bicyclic 1,4-diazepanones and therapeutic uses thereof | MYLK2, MUSK, MYLK | DPP4 2008/4885CA2 987/4885DPP8 3037/4885 |
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | DPP4 997/4885CA2 290/4885DPP8 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.